home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

56.85 -1.14 (-1.97%)

Streaming Delayed Price Updated: 2:01 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

34 35 Next >

3 Disruptors I Love Right Now ↗

May 30, 2023

These stocks could deliver huge returns as the companies transform the economy.

Via The Motley Fool

Prediction: These 2 Stocks Could Double In the Next Year ↗

May 28, 2023

It would be a continuation of solid recent performances.

Via The Motley Fool

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

May 27, 2023

These stocks might not remain under $100 for too much longer.

Via The Motley Fool

2 Supercharged Stocks to Buy With $100 ↗

May 27, 2023

These stocks are climbing in the double digits.

Via The Motley Fool

2 Top Trends to Invest $5,000 in Right Now ↗

May 25, 2023

Renewable energy and gene-editing medical therapies are poised to grow exponentially.

Via The Motley Fool

Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health ↗

May 25, 2023

Both stocks are recovering after big losses last year.

Via The Motley Fool

CRISPR Therapeutics Earnings Perspective: Return On Capital Employed ↗

May 23, 2023

Via Benzinga

Analyst Expectations for CRISPR Therapeutics's Future ↗

May 23, 2023

Via Benzinga

Is CRISPR Therapeutics Stock a Buy Now? ↗

May 13, 2023

The clinical-stage biotech company has been on the rise.

Via The Motley Fool

Is It Too Late to Buy CRISPR Stock? ↗

April 27, 2023

Five reasons to buy the promising biotech stock now.

Via The Motley Fool

A Good Week For The Market But A Pause In The Biotech Rally ↗

May 22, 2023

Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness.

Via Talk Markets

Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It ↗

May 21, 2023

Her investing thesis for holding it is probably the same as ever.

Via The Motley Fool

Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You? ↗

May 21, 2023

It's facing a few issues that are practically guaranteed to affect shareholder returns.

Via The Motley Fool

3 Biotech Stocks That Are Revolutionizing Healthcare in 2023 ↗

May 19, 2023

Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher.

Via InvestorPlace

Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings

May 18, 2023

Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.

Via MarketBeat

2 Stocks You'll Be Glad You Bought at These Prices ↗

May 17, 2023

Bear markets create opportunities to buy high-growth stocks at discounted valuations.

Via The Motley Fool

2 Soaring Growth Stocks That Could Rocket Even Higher ↗

May 16, 2023

One of these stocks is up 57% this year, and the other one has more than tripled already.

Via The Motley Fool

Why These 3 Nasdaq Stocks Were Glowing Green This Week ↗

May 11, 2023

These three biopharmaceutical stocks rocketed higher this week.

Via The Motley Fool

Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades' ↗

May 10, 2023

On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners said CRISPR Therapeutics AG (NASDAQ: CRSP) reported strong

Via Benzinga

Why CRISPR Therapeutics Stock Is on Fire Today ↗

May 09, 2023

Thanks to the gene-editing pioneer having a pipeline chock-full of deep value and a possible regulatory approval on tap, investors are bidding up shares today.

Via The Motley Fool

Something Happened In Biotech Last Week ↗

May 08, 2023

Biotech stocks were more constructive last week with some sharp moves up.

Via Talk Markets

This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock ↗

May 06, 2023

Vertex Pharmaceuticals faces limited competition in its core area of expertise, has a top-shelf CEO, and is building out a profoundly valuable pipeline of next-generation assets.

Via The Motley Fool

1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May ↗

May 04, 2023

This market-beating biotech stock still has more room to run.

Via The Motley Fool

3 Top Healthcare Stocks to Buy in May ↗

May 04, 2023

You'll want to hold onto these innovative companies for the long term.

Via The Motley Fool

3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers ↗

May 02, 2023

Cathie Wood is loading up on these biotech stocks.

Via The Motley Fool

Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector ↗

May 01, 2023

A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro...

Via Talk Markets

Why CRISPR Therapeutics Just Became an Even Better Buy ↗

April 26, 2023

Is this a no-brainer investment to add to your portfolio?

Via The Motley Fool

3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat ↗

April 25, 2023

Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat.

Via InvestorPlace

With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023 ↗

April 24, 2023

Via Benzinga

The Best Stocks to Invest $20,000 in Right Now ↗

April 23, 2023

You'll want to hold on to these top stocks for the long term.

Via The Motley Fool

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com